{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:37:32Z","timestamp":1765370252319,"version":"3.40.5"},"reference-count":24,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T00:00:00Z","timestamp":1693612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Obstet and Gynaecol"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>There is no conclusive data on the prognosis of patients who receive paclitaxel\u2010carboplatin (TC) plus bevacizumab therapy for advanced neuroendocrine carcinoma (NEC) of the uterine cervix, a rare histological subtype of cervical cancer. Thus, the aim of this study was to determine the efficacy of TC chemotherapy plus bevacizumab and bevacizumab single maintenance therapy for advanced NEC of the cervix.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective review of patients who received TC plus bevacizumab therapy for metastatic, recurrent, or persistent NEC of the cervix at seven institutions between 2015 and 2020. Relevant data were extracted from the patients' medical records and analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seven patients, including six with small\u2010cell NEC and one with large\u2010cell NEC, were included for analysis. Three patients received bevacizumab single maintenance therapy following TC plus bevacizumab therapy, whereas four patients did not receive bevacizumab single maintenance therapy. The median overall survival and progression\u2010free survival of the patients who received bevacizumab single maintenance therapy were longer than those of the patients who did not receive the therapy (34\u2009months vs. 10.5\u2009months and 19\u2009months vs. 5\u2009months, respectively). However, the patients who received bevacizumab single maintenance therapy had received cisplatin\u2010based chemotherapy previously.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>On the premise that cisplatin\u2010based chemotherapy is administered as the first\u2010line treatment for advanced NEC of the cervix, bevacizumab single maintenance therapy following TC plus bevacizumab may be considered the second\u2010 or third\u2010line treatment. However, the risk of adverse events, such as intestinal perforation, should be discussed with patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jog.15783","type":"journal-article","created":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T10:14:05Z","timestamp":1693649645000},"page":"2868-2874","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Paclitaxel\u2010carboplatin plus bevacizumab therapy for advanced neuroendocrine carcinoma of the uterine cervix: A retrospective case series"],"prefix":"10.1111","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2455-7669","authenticated-orcid":false,"given":"Saki","family":"Kotaka","sequence":"first","affiliation":[{"name":"Department of Gynecologic Oncology Aichi Cancer Center Hospital  Nagoya Aichi Japan"},{"name":"Department of Obstetrics and Gynecology Mie University School of Medicine  Tsu Mie Japan"},{"name":"Department of Obstetrics and Gynecology Kuwana City Medical Center  Kuwana Mie Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9773-2520","authenticated-orcid":false,"given":"Eiji","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Mie University School of Medicine  Tsu Mie Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Kawai","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Toyohashi Municipal Hospital  Toyohashi Aichi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Mie University School of Medicine  Tsu Mie Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Kishigami","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Toyota Memorial Hospital  Toyota Aichi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaharu","family":"Yamawaki","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Ise Red Cross Hospital  Ise Mie Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Nagao","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Yokkaichi Municipal Hospital  Yokkaichi Mie Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirata","family":"Toru","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Kuwana City Medical Center  Kuwana Mie Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0834-9285","authenticated-orcid":false,"given":"Shiro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology Aichi Cancer Center Hospital  Nagoya Aichi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,9,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/jog.15284"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4447-x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.11.010"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11086"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3326"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08772-x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.970985"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31607-0"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112435"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112187"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.05.682"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.12611"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_8_15_1","unstructured":"Cancer Therapy Evaluation Program.Common terminology criteria for adverse events (CTCAE) version 5.0. National Cancer Institute. (Internet). 2017 Nov. [Cited 9 May 2023.] Available from.https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyac034"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2023.34.e60"},{"issue":"445","key":"e_1_2_8_18_1","first-page":"e1","article-title":"Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression\u2010free survival in patients with recurrent high\u2010grade neuroendocrine cervical cancer: a neuroendocrine cervical tumor registry (NeCTuR) study","volume":"228","author":"Frumovitz M","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.10.040"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyw143"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2022.101013"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000506446"},{"key":"e_1_2_8_23_1","first-page":"81","article-title":"Recurrent small cell carcinoma of the uterine cervix responding to combined therapy with paclitaxel, cisplatin, and bevacizumab: a case report","volume":"43","author":"Hirasawa T","year":"2018","journal-title":"Tokai J Exp Clin Med"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.09.018"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.04.019"}],"container-title":["Journal of Obstetrics and Gynaecology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jog.15783","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T02:08:19Z","timestamp":1702951699000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/jog.15783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,2]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1111\/jog.15783"],"URL":"https:\/\/doi.org\/10.1111\/jog.15783","archive":["Portico"],"relation":{},"ISSN":["1341-8076","1447-0756"],"issn-type":[{"type":"print","value":"1341-8076"},{"type":"electronic","value":"1447-0756"}],"subject":[],"published":{"date-parts":[[2023,9,2]]},"assertion":[{"value":"2023-05-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}